COMPARATIVE EVALUATION OF INTRAVITREAL DICLOFENAC PLUS BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF NAÏVE DIABETIC MACULAR EDEMA: A RANDOMIZED CONTROLLED TRIAL

OBJECTIVE: To evaluate the therapeutic effects of intra-vitreal injection Bevacizumab combined with Diclofenac-Na versus alone in treatment naïve diabetic macular edema. METHODS: In this prospective, randomized interventional clinical trial, 40 eyes participants were enrolled for trial conducted at an Ophthalmology department Qazi Hussain Medical Complex, Nowshera. Twenty each included and bevacizumab plus diclofenac group via random sampling technique. The main outcome variable was a change best-corrected visual acuity (BC-VA) log MAR 4th, 12th 24th week. secondary outcomes mean central subfield thickness (CSFT) macula possible injection-related side effects. RESULTS: Marked improvement BC-VA observed both groups (mean Log MAR: 0.324±0.411 0.562±0.388 combination group, respectively). difference favor group; however, level didn’t achieve statistical significance (p = 0.08). Significant decrease CSFT noted reductions: 178.02 ± 166.42, 214.55 132.65) combination, Comparison changes between revealed that decreased more than bevacizumab, but statistically insignificant 0.07). Neither related nor any marked intraocular pressure either groups. CONCLUSION: edema, superiority therapy over evident, esp. regard to structural macula.